EP 904 PILL – IDENTIFICATION, SIDE EFFECTS, PRECAUTIONS

The pill imprinted with EP 904 is an oral tablet of Lorazepam at a strength of 0.5 mg. Lorazepam is an intermediate-acting benzodiazepine primarily prescribed under the brand name Ativan (as well as various generic equivalents) for anxiety disorders and short-term symptom relief.

Pill Identification

Attribute – Specification

• Active Ingredient – Lorazepam (0.5 mg)
• Imprint – EP 904 debossed on one side; plain on the reverse
• Color – White
• Shape / Form – Round, flat-faced, beveled-edge tablet
• Diameter – Approximately 5 mm
• Drug Class – Benzodiazepine
• Legal Status – Prescription only; DEA Schedule IV controlled substance (US)
• Primary Manufacturers/Packagers – Excellium Pharmaceutical, Leading Pharma, Major Pharmaceuticals

Mechanism of Action

Lorazepam functions as a positive allosteric modulator of gamma-aminobutyric acid type A receptors in the central nervous system:

• GABA Potentiation: It binds to a specific benzodiazepine site distinct from the GABA-binding pocket at the subunit interface of the receptor.
• Chloride Conductance: This binding increases the receptor’s affinity for endogenous GABA, resulting in more frequent opening of the integral chloride ion channel.
• Hyperpolarization: The influx of negatively charged chloride ions hyperpolarizes the postsynaptic neuronal membrane, elevating the threshold needed for an action potential. This produces generalized central nervous system depression, manifesting as anxiolytic, sedative, hypnotic, muscle relaxant, and anticonvulsant effects.

Standard Indications & Dosage Guidelines

• Dosages must always be individualized based on clinical indication, patient age, hepatic function, and treatment response.

• General Anxiety Disorders:
• Typical adult starting dose: 1 mg to 3 mg per day, divided into 2 or 3 doses. The largest portion of the daily dose is frequently taken right before bedtime to minimize daytime sedation.
• Maintenance range: 2 mg to 6 mg per day in divided doses (rarely exceeding 10 mg/day).

• Insomnia Due to Anxiety:
• Typical adult dose: 0.5 mg to 2 mg taken once daily at bedtime.

• Elderly or Debilitated Patients:
• Initial dose: 0.5 mg to 1 mg per day in divided doses. Lower initial doses are critical in this demographic to prevent severe ataxia, oversedation, and fall-related injuries.

• Duration: Intended primarily for short-term use (typically 2 to 4 weeks). Long-term continuous therapy is discouraged due to tolerance and dependency risks.

Side Effects

Common Side Effects

• Drowsiness, excessive daytime sedation, and lightheadedness
• Ataxia, impaired coordination, and unsteadiness
• Fatigue and asthenia (muscle weakness)
• Dizziness and mental confusion
• Blurred vision

Severe / Adverse Reactions

• Paradoxical excitement (increased agitation, hostility, rage, or hallucination—more common in pediatric and geriatric populations)
• Anterograde amnesia (inability to form new memories while medicated)
• Severe respiratory depression
• Hypotension and syncope
• Severe allergic or dermatologic hypersensitivity reactions

Precautions & Interactions

• Drug Interactions:
• CNS Depressants & Alcohol: Concomitant use with alcohol, sedatives, sleeping aids, tricyclic antidepressants, or first-generation antihistamines exponentially increases the risk of severe CNS depression, coma, and fatal respiratory collapse.
• Opioids: Concurrent use with opioid analgesics or cough formulations carries extreme risks of profound sedation, respiratory arrest, and death.
• Probenecid / Valproate: Can inhibit lorazepam glucuronidation, raising serum levels and extending clearance times.

• Hepatic & Renal Impairment: Lorazepam is metabolized predominantly via direct hepatic glucuronidation (without significant cytochrome P450 pathway involvement) into an inactive glucuronide. While generally safer than oxidatively cleared benzodiazepines in mild liver dysfunction, extreme caution is still required in severe hepatic or renal failure.
• Respiratory Compromise: Use cautiously in individuals with chronic obstructive pulmonary disease (COPD) or severe sleep apnea syndrome.
• Myasthenia Gravis: Relative contraindication due to muscle-relaxing properties exacerbating muscle fatigue.
• Pregnancy & Lactation: Benzodiazepines cross the placenta and enter breast milk. Use during pregnancy carries risks of congenital malformations and neonatal withdrawal/sedation (“floppy infant syndrome”).

Black Box Warnings & Risks

• Concomitant Use with Opioids: Concomitant prescribing of benzodiazepines and opioids increases the risk of profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients with inadequate alternative treatment options.
• Abuse, Misuse, and Addiction: Benzodiazepine use exposes users to the risks of abuse and addiction, which can lead to overdose and death. Assess each patient’s risk prior to prescribing and monitor regularly.
• Physical Dependence and Withdrawal: Continued use may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dose reduction can precipitate life-threatening withdrawal symptoms, including seizures, delirium tremens, psychosis, severe tremors, and rebound anxiety. Never discontinue lorazepam abruptly; tapering under medical supervision is mandatory.